PHIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PHIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Phio Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-10.75 Mil, and Market Cap is $3.76 Mil. Therefore, Phio Pharmaceuticals's FCF Yield % for today is -285.57%.
The historical rank and industry rank for Phio Pharmaceuticals's FCF Yield % or its related term are showing as below:
During the past 13 years, the highest FCF Yield % of Phio Pharmaceuticals was -8.84%. The lowest was -33715.34%. And the median was -114.31%.
Phio Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.
The historical data trend for Phio Pharmaceuticals's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phio Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial | -138.44 | -56.72 | -87.99 | -240.92 | -377.60 |
Phio Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
FCF Yield % | Get a 7-Day Free Trial | -212.80 | -167.52 | -194.54 | -332.94 | -332.87 |
For the Biotechnology subindustry, Phio Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Phio Pharmaceuticals's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Phio Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | -10.754 | / | 2.8479708 | |
= | -377.60% |
Phio Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | -2.37 | * | 4 | / | 2.8479708 | |
= | -332.87% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phio Pharmaceuticals FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Phio Pharmaceuticals's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert J Bitterman | director | C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581 |
Robert L Ferrara | director | 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752 |
Patricia A Bradford | director | UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422 |
Gerrit Dispersyn | officer: Chief Development Officer | 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752 |
John A Barrett | officer: Chief Development Officer | 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752 |
Geert Cauwenbergh | director, officer: President and CEO | 1 STULTS DRIVE, PLAINSBORO NJ 08536 |
Alexey Eliseev | officer: Chief Business Officer | 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752 |
Jonathan E Freeman | director | 257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH MA 01752 |
Curtis Lockshin | director | 4400 BISCAYNE BOULEVARD, SUITE 950, MIAMI FL 33137 |
H. Paul Dorman | director | 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581 |
Opko Health, Inc. | 10 percent owner | 4400 BISCAYNE BLVD., MIAMI FL 33137 |
Advanced Rna Technologies, Llc | 10 percent owner | 1 KENDALL SQUARE BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139 |
Keith L Brownlie | director | 777 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591 |
Pamela Pavco | officer: Chief Development Officer | C/O RXI PHARMACEUTICALS CORPORATION, 1500 WEST PARK DRIVE, WESTBOROUGH MA 01581 |
Caitlin Kontulis | officer: Secretary and Controller | 1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH MA 01581 |
From GuruFocus
By PRNewswire PRNewswire • 12-21-2022
By PRNewswire PRNewswire • 02-10-2023
By PRNewswire PRNewswire • 07-06-2022
By PRNewswire PRNewswire • 05-18-2023
By Marketwired • 08-21-2023
By PRNewswire PRNewswire • 04-18-2023
By PRNewswire PRNewswire • 05-31-2023
By PRNewswire PRNewswire • 05-11-2023
By PRNewswire PRNewswire • 01-06-2023
By PRNewswire PRNewswire • 01-25-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.